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A significant fraction of disease-causing mutations affects pre-
mRNA splicing. These mutations can generate both aberrant and
correct transcripts, the level of which varies among different
patients. An inverse correlation was found between this level and
disease severity, suggesting a role for splicing regulation as a genetic
modifier. Overexpression of splicing factors increased the level of
correctly spliced RNA, transcribed from minigenes carrying disease-
causing splicing mutations. However, whether this increase could
restore the protein function was unknown. Here, we demonstrate
that overexpression of Htra2-b1 and SC35 increases the level of
normal cystic fibrosis transmembrane conductance regulator
(CFTR) transcripts in cystic-fibrosis-derived epithelial cells carrying
the 3849þ 10 kb C-T splicing mutation. This led to activation of
the CFTR channel and restoration of its function. Restoration was
also obtained by sodium butyrate, a histone deacetylase inhibitor,
known to upregulate the expression of splicing factors. These results
highlight the therapeutic potential of splicing modulation for
genetic diseases caused by splicing mutations.
Keywords: cystic fibrosis; cystic fibrosis transmembrane conduc-
tance regulator functional restoration; sodium butyrate; splicing
factors; splicing pattern modulation
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INTRODUCTION
Cystic fibrosis (CF) is a common, severe autosomal recessive
disease caused by mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene (Kerem et al, 1989). A
significant fraction (13%) of CFTR mutations affects the pre-
mRNA splicing of the gene (http://www.genet.sickkids.on.ca/cftr),
by disrupting or generating intronic splicing motifs, required for
exon recognition. In addition, there are mutations and poly-
morphisms that disrupt exonic splicing motifs, which also affect
the splicing pattern. All these mutations can be divided into two
groups on the basis of their effect on the splicing pattern. One
group includes mutations that completely abolish exon recogni-
tion (such as 621þ 1 G-T, 711þ 1 G-T and 15251 G-A),
resulting in a relatively severe disease due to a complete absence
of correctly spliced transcripts (Zielenski et al, 1993; Ramalho
et al, 2003). The second group includes mutations that generate
both aberrantly and correctly spliced transcripts (such as
3849þ 10 kb C-T, 327226 A-G, IVS8-5T, D565G and
G576A), the level of which varies among patients and among
organs of the same patient (Ramalho et al, 2002; Pagani et al,
2003; reviewed in Nissim-Rafinia & Kerem, 2002). These patients
often have a relatively mild phenotype, but with variable disease
expression from minimal lung disease, pancreatic sufficiency and
male fertility to relatively severe disease in all the involved organs
(Augarten et al, 1993; Kerem et al, 1997). This variable disease
expression is inversely correlated with the level of correctly
spliced transcripts, such that lower levels are associated with
severe disease and higher levels with a milder phenotype. These
results suggested that splicing regulation has a role as a genetic
modifier of disease severity in patients carrying splicing mutations
that generate normal transcripts (Nissim-Rafinia & Kerem, 2002).
Splicing is regulated through the interaction of a complex
repertoire of splicing factors with various splicing motifs (reviewed
in Black, 2003). Differences in the levels of functional splicing
factors were found among different tissues, which has been
suggested to regulate the tissue-specific level of alternatively
spliced transcripts. As the first step in understanding the role of
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splicing regulation as a modifier of CF, the effect of overexpression
of splicing factors on the level of correctly spliced CFTR transcripts
was studied in minigenes carrying CFTR splicing mutations
(Nissim-Rafinia et al, 2000; Pagani et al, 2000, 2003; Aznarez
et al, 2003). Among these were mutations that lead to partial
skipping of exons 9 and 12, the 50 end of exon 13 and the
3849þ 10 kb C-T mutation, which leads to partial inclusion of
84 base pairs (bp) from intron 19. Most (10 out of 11) of the
minigenes were modulated by splicing factors. Higher levels of
correctly spliced transcripts were generated by several of these
factors (Htra-a and E4-ORF3, which promoted exons 13 and 9
inclusion, respectively, and hnRNP A1 and E4-ORF6, which
promoted skipping over the cryptic 84 bp exon). However,
whether the increased levels of correctly spliced transcripts can
restore the forskolin-stimulated CFTR function remains unknown.
Here, we demonstrate that an increase in the level of correctly
spliced RNA, transcribed from an endogenous CFTR allele
carrying the 3849þ 10 kb C-T mutation, activated the CFTR
channel and restored its function. This was obtained by over-
expression of SR (SC35) and SR-like (Htra2-b1) splicing factors,
which promoted skipping of the 84 bp exon and increased
the level of full-length CFTR transcripts. The same effect was
obtained by administration of sodium butyrate (NaBu), a histone
deacetylase inhibitor, previously shown to upregulate the
expression of splicing factors (Chang et al, 2001; Brichta et al,
2003). These results explain the correlation between the level of
correctly spliced CFTR transcripts and disease severity, and
provide the required basis for the development of therapeutic
approaches for patients carrying splicing mutations in CF as in
other human diseases.
RESULTS AND DISCUSSION
CFTR splicing modulation by splicing factors
To study the potential of splicing modulation to restore the CFTR
function, cells comprising the entire CFTR coding region, carrying
a splicing mutation, were required. We established an epithelial
cell line (CFP15a) from a nasal polyp of a CF patient carrying the
3849þ 10 kb C-T splicing mutation. This mutation generates a
donor site in intron 19, which can lead to inclusion of 84 bp
containing an in-frame stop codon (Highsmith et al, 1994).
Reverse transcription–PCR (RT–PCR) showed that 2072% of the
transcripts include the cryptic exon (Fig 1A). These aberrant
transcripts were transcribed only from the 3849þ 10 kb C-T
allele. The correctly spliced transcripts (80%) were transcribed
from both alleles, and as the relative contribution of each allele
was unknown, we analysed throughout the study the relative level
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Fig 1 | Effect of overexpression of splicing factors on the splicing pattern of CFTR exons in CFP15a cells carrying the 3849þ 10 kb C-T splicing
mutation. Analysis of the splicing pattern of the cryptic 84 bp exon (A) and exon 9 (B). The top panels show examples of Genescan analysis of
RT–PCR products from untransfected cells (left) and cells transfected (right) with Htra2-b1 (A) and ASF/SF2 (B). Percentages denote relative levels
of correct and aberrant transcripts and numbers denote sizes of RT–PCR products (304 and 388 bp in (A), and 447 and 264 bp in (B)). The bottom
panels show the effect of splicing factors on the level of aberrant transcripts. The grey columns represent a significant effect (Po0.01) using the
Mann–Whitney U-test, adjusted with Bonferroni correction for eight comparisons. The white columns represent no effect. Error bars, standard
deviation; UT, untransfected.
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We analysed the effect of transient transfection of splicing
factors on the level of aberrantly spliced CFTR transcripts in
CFP15a cells, with cellular and viral factors. RT–PCR showed that
Htra2-b1, SC35 and ASF/SF2 promoted skipping of the 84 bp exon
and led to a significant decrease in the relative level of aberrantly
spliced transcripts, whereas SRp20, hnRNP A1 and E4-ORF6 had
no significant effect (Fig 1A). E4-ORF3 promoted inclusion and led
to a significant increase in the relative level of aberrant transcripts.
As a control, cells were transfected with green fluorescent protein.
No effect was observed, indicating that the change in the splicing
pattern was specific to the splicing factors. We further analysed
the level of Htra2-b1, ASF/SF2, SRp20 and hnRNP A1 by
immunoblotting (Fig 2). The results showed an increase in the
expression of all factors, including those that had no effect
(hnRNP A1 and SRp20). Furthermore, Htra2-b1 and hnRNP A1 are
highly overexpressed; however, the latter did not affect the
splicing pattern. This could result from different binding efficien-
cies of the splicing factors to splicing motifs and/or changes in
relative concentrations of other cellular factors. In summary,
our results show that overexpression of splicing factors can
modulate the splicing pattern of the cryptic 84 bp exon in RNA
transcribed from endogenous CFTR alleles carrying the 3849þ
10 kb C-T mutation.
Restoration of the CFTR function was expected to result from
increasing the level of normal and full-length CFTR transcripts.
The CFTR gene comprises 27 constitutively spliced exons;
however, several exons (3, 4, 9, 12, 14a, 16, 17b and 22)
undergo, in some individuals, partial aberrant splicing that
generates nonfunctional CFTR proteins (Bienvenu et al, 1996).
These exons might be modulated, leading to a decrease in the
level of full-length CFTR transcripts. RT–PCR of exon 9 showed
that the relative level of aberrantly spliced transcripts lacking
the exon is 6174% (Fig 1B). Overexpression of ASF/SF2 pro-
moted skipping of exon 9 and significantly increased the level
of aberrantly spliced transcripts, whereas overexpression of all
other factors had no effect. For other exons, see supplementary
information online. Taken together, Htra2-b1, SC35 and ASF/SF2
promoted skipping of the cryptic 84 bp exon. Whereas Htra2-b1
and SC35 had no effect on the splicing pattern of other exons
and thus were expected to increase the level of normal and
full-length CFTR transcripts, ASF/SF2 promoted exon 9 skipping,
and therefore its effect on the level of normal transcripts could
not be predicted.
CFTR activity restoration by Htra2-b1 and SC35
The CFTR protein is a cyclic AMP-stimulated Cl channel, which
also regulates other transport proteins. To study the effect of
splicing modulation on the CFTR function, we measured Cl
efflux (Fig 3A). The analysis showed no forskolin-stimulated
chloride efflux, indicating that the CFTR channels in these cells
are inactive, as found in CFP22a cells (DF508/DF508) and IB3
cells (W1282X/DF508).
Next, we analysed the effect of overexpression of splicing
factors on the function of the CFTR protein. Overexpression of
Htra2-b1 and SC35 activated the CFTR channel and restored its
function, indicating that the increase in the level of normal
transcripts was sufficient for this activation (Fig 3B). We studied
the effect of Htra2-b1 on the CFTR function in CFP22a and IB3
cells, in which the CFTR RNA level is similar to that of CFP15a
cells (data not shown). No restoration of the CFTR channel activity
was found (Fig 3C), indicating that the Htra2-b1 restoration in
CFP15a cells was obtained through modulation of the CFTR
splicing pattern. Overexpression of ASF/SF2 did not activate the
CFTR channel (Fig 3B), indicating that the level of normal and
full-length CFTR transcripts was insufficient for CFTR activation.
Overexpression of the other factors did not restore the CFTR
function (Fig 3D). Altogether, these results show that only factors
that significantly increased the relative level of normal CFTR
transcripts led to restoration of the CFTR Cl efflux. These results
support our hypothesis that the splicing machinery is a modifier of
disease severity in patients carrying splicing mutations (Nissim-
Rafinia & Kerem, 2002). A recent study in mice identified a
putative splicing factor (sodium channel modifier 1, SCNM1) that
modifies disease severity in mice homozygous for a splicing
mutation in the Scn8a gene. Mice carrying normal alleles of
SCNM1 show chronic movement disorder; however, mice
carrying a stop mutation in this gene show reduced levels of
correctly spliced Scn8a transcripts and a lethal neurological
disease (Buchner et al, 2003). These results provide the first
evidence for the role of splicing regulation as a genetic modifier.
CFTR splicing modulation and activity restoration
We further analysed the effect of NaBu on CFTR function, on the
basis of previous studies showing that NaBu upregulated the
expression of Htra2-b1 and SR proteins in spinal muscular atrophy
(SMA) cells (Chang et al, 2001; Brichta et al, 2003). In CFP15a
cells, NaBu affected the splicing pattern in an inverse ‘bell-shape’
manner, such that 5–250 mM NaBu significantly decreased the
level of aberrantly spliced transcripts, whereas lower and higher
concentrations had no effect (Fig 4A). NaBu had no effect on the














































Fig 2 | Increase of the protein level of splicing factors transfected into
CFP15a cells. The top panels show tagged plasmids (endogenous and
tagged of different sizes) and the bottom panels show untagged plasmids
(endogenous and exogenous of same size). UT, untransfected.
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(data not shown). We then analysed the effect of NaBu on the
CFTR function. Activation of the CFTR channel was achieved
only by 5–250 mM NaBu, which significantly increased the level
of normal CFTR transcripts, whereas other concentrations had
no effect on the CFTR Cl efflux (Fig 5A). NaBu was also
administered to CFP22a and IB3 cells and no activation was
detected (Fig 5B), indicating that the NaBu restoration in CFP15a
cells was obtained through modulation of the CFTR splicing
pattern.
As NaBu has the potential to upregulate gene expression, we
evaluated the possibility that NaBu, in addition to its effect on the
splicing pattern, upregulated the expression of the CFTR gene in
CFP15a cells. For this, we analysed the level of CFTR RNA before
and after treatment with 5–250mM NaBu. The results showed no
change in the level of CFTR RNA (Fig 6), indicating no effect of
NaBu on the expression of the CFTR gene. Thus, the restoration of
the CFTR function by NaBu resulted from splicing modulation
only. We then analysed the effect of NaBu on the endogenous
level of several splicing factors by using anti-Htra2-b1 and a
specific antibody for SR proteins, mAb104. Our results showed no
significant increase in the expression of these factors (data not
shown). However, as splicing is regulated by 4100 factors, it is
possible that other factors were affected by NaBu in the CF
epithelial cell line used in this study.
In many human genetic diseases, a substantial fraction of
patients carry mutations that affect the correct splicing. A total of
10–15% of disease-causing mutations disrupt intronic splicing
motifs and an additional B35% disrupt exonic motifs, which lead
to aberrant splicing (reviewed in Cartegni et al, 2002). As found
for CF, patients who carry splicing mutations causing SMA show
extensive variability in disease severity, inversely correlated with
the level of correctly spliced RNA containing exon 7 (Gavrilov
et al, 1998). Overexpression of splicing factors (including Htra2-
b1) promoted exon 7 inclusion and increased the level of correctly
spliced SMN2 RNA (Hofmann et al, 2000). It is interesting to note
that Htra2-b1 in our study also increased the level of correctly
spliced transcripts, but by exon skipping.
Splicing modulation of SMN exon 7 was also demonstrated by
treating SMA-derived cells with NaBu. This led to an increase in
the level of correctly spliced RNA and SMN protein (Chang et al,
2001; Brichta et al, 2003). However, the effect of the splicing
modulation on protein function was not studied. As found for
overexpression of Htra2-b1, NaBu promoted skipping of the CFTR


























































































Fig 3 | Activation of CFTR Cl efflux by overexpression of splicing factors. CFTR activity in (A) T84, CFP15a, CFP22a and IB3 cells, (B) CFP15a cells
following transfection with Htra2-b1, SC35 and ASF/SF2, (C) CFP22a and IB3 cells following transfection with Htra2-b1 and (D) CFP15a cells following
transfection with SRp20, hnRNP A1, E4-ORF6 and E4-ORF3. The filled symbols indicate activation of the CFTR Cl efflux and the open symbols
indicate no effect. The arrows indicate the time of forskolin administration.
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NaBu treatment of SMA-like mice resulted in an increased level of
full-length SMN protein, which resulted in a limited improvement
of clinical symptoms (Chang et al, 2001).
Several small molecules, such as aclarubicin, sodium vanadate
and valproic acid, also increased the level of correctly spliced
SMN2 transcripts and proteins (Andreassi et al, 2001; Zhang et al,
2001; Brichta et al, 2003). Valproic acid also upregulated SMN2
gene expression and thus further contributed to this increase.
Additional molecules such as EGCG and kinetin increased the
level of correct IKAP spliced RNA and protein by splicing
modulation in familial dysautonomia-derived cells carrying the
IVS20þ 6 T-C splicing mutation (Anderson et al, 2003;
Slaugenhaupt et al, 2004). Interestingly, in the case of EGCG,
downregulation of hnRNP A2/B1 expression was found.
The small molecules used to modulate the splicing pattern are
expected to affect the pattern of exons in the same or other genes,
emphasizing the need to develop therapeutic approaches with
specificity to the desired exon. One such approach is using
antisense oligonucleotides designed to inhibit cryptic splicing.
This resulted in a decrease in the level of aberrant CFTR transcripts
containing the 84 bp exon (Friedman et al, 1999). In another
approach, chimeric antisense oligonucleotides comprising two
parts are designed: one is complementary to the aberrantly spliced
exon and provides exon specificity, and the other contains binding
motifs for recruitment of splicing factors to the mutation site
(Cartegni & Krainer, 2003; Skordis et al, 2003). An increase in the
binding of splicing factors by such oligonucleotides resulted in an
increased level of SMN2 exon 7 and BRCA1 exon 18 inclusion.
Another possible approach is identification of small molecules
with specific effect.
In summary, the results presented in this study provide direct
evidence that increasing the level of normal transcripts can restore
protein function. This indicates that in cells carrying splicing
mutations, the level of correctly spliced transcripts deter-
mines CFTR function and explains the previously found correla-
tion between the level of correctly spliced CFTR transcripts
and disease severity among patients and among organs of the
same patient.
METHODS
Transfection of splicing factors and NaBu administration. A total
of 105 cells were plated for RNA analysis into six-well plates 24 h
before transfection. A total of 104 cells were plated for functional
analysis into 96-well plates 72 h before transfection. Transfection
efficiency was optimized using variations in the amount of
plasmid DNA and MAX-2 reagent (Eurogentec). A 1 and 0.15mg
portion of each plasmid was transfected into six- and 96-well
plates respectively. Cells were further grown for 48 h. Only
experiments in which 50–60% of the cells were transfected were
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Fig 4 | Effect of NaBu on the splicing pattern of CFTR exons in CFP15a cells. Analysis of the splicing pattern of the cryptic 84 bp exon (A) and
exon 9 (B). The top panels show examples of Genescan analysis of RT–PCR products from cells treated with 50 nM (left) and 50 mM (right) NaBu.
Percentages and numbers in the top panels are as in Fig 1. The bottom panels show the effect of different NaBu concentrations on the level of
aberrant transcripts. The grey bars show significant effect (Po0.01, Mann–Whitney U-test, adjusted with Bonferroni correction for seven comparisons)
and the white bars show no effect. Error bars, standard deviation; UT, untreated.
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included in the analysis. NaBu was added for 4 h, 6 days after
plating of cells. Experiments were repeated 3–7 times.
RNA extraction and RT–PCR analysis. Total RNA was purified
using the ULTRASPEC RNA Kit (BIOTECX). Complementary DNA
synthesis and splicing pattern analysis were performed as
described previously (Rave-Harel et al, 1997; Nissim-Rafinia
et al, 2000). Primers and PCR conditions are listed in supplemen-
tary Table 1 online.
CFTR functional analysis. CFTR function was measured by Cl
efflux using the Cl-sensitive fluorescent indicator MQAE
(Mansoura et al, 1999). For evaluation of CFTR activation, the
difference between fluorescence intensity at the reading time (Ft)
and at the beginning of the experiment (F0) was calculated.
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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